ABBV ABBV
Company Analysis
Latest News
AbbVie's Rinvoq Shows Superiority Over Humira in Head-to-Head Rheumatoid Arthritis Study
AbbVie announced positive topline results from its Phase 3b/4 SELECT-SWITCH study, a head-to-head trial comparing Rinvoq (upadacitinib) to Humira (adalimumab)...
AbbVie completes Bretisilocin acquisition; FDA expands RINVOQ label
On October 17, 2025, AbbVie announced the completion of its acquisition of Gilgamesh Pharmaceuticals' Bretisilocin, a move seen as strengthening its...
ABBV edges lower as investors digest strong Q2 earnings and guidance hike
AbbVie Inc. closed at $226.22 on October 15, 2025, down 1.27% from the previous session, continuing a modest decline over the past week despite strong business...
AbbVie Faces Potential Patent Battle Over Newly Acquired Depression Drug
AbbVie is facing a potential legal challenge from Enveric Biosciences (NASDAQ: ENVB) regarding its recently acquired major depressive disorder candidate,...
AbbVie Set for $1.64 Dividend Payout; Ex-Dividend Date October 15, 2025
AbbVie Inc. (ABBV) will go ex-dividend on October 15, 2025, with shareholders of record set to receive a $1.64 per share dividend payable on November 14, 2025....
AbbVie Gains FDA Approval for Expanded Rinvoq Use; New Oncology Data to Be Presented at ESMO
On October 13, 2025, AbbVie announced that the FDA approved an updated indication for Rinvoq, allowing broader use in adults with moderately to severely active...
AbbVie's RINVOQ Receives FDA Approval for Expanded Use in IBD Treatment
The U.S. Food and Drug Administration (FDA) has approved an updated indication for AbbVie's RINVOQ (upadacitinib) for the treatment of adults with moderately...
AbbVie to Present New Oncology Data at ESMO; FDA Expands Rinvoq Indication
On October 13, 2025, AbbVie announced it will present new data from its antibody-drug conjugate (ADC) platform at the upcoming ESMO 2025 Congress, highlighting...
AbbVie Announces FDA Approval for RINVOQ and New Oncology Data Presentation
On October 13, 2025, AbbVie Inc. announced two significant developments: the FDA approved an updated indication statement for RINVOQ, expanding its use for...
AbbVie Receives Expanded FDA Approval for RINVOQ® in Inflammatory Bowel Disease, Boosting Treatment Options
On October 13, 2025, AbbVie announced it received approval from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) for...
Piper Sandler Raises AbbVie Price Target to $284, Maintains Overweight Rating
On October 10, 2025, Piper Sandler raised its price target for AbbVie Inc (ABBV) from $231.00 to $284.00 while maintaining an 'Overweight' rating, signaling...